Navigation Links
CBI and PharmaVoice Announce Recipients of the Strategic Patient Adherence Awards
Date:4/30/2008

WOBURN, Mass., April 30 /PRNewswire/ -- AstraZeneca, Eli Lilly and Rx Canada received top honors at the 2008 Strategic Patient Adherence (SPA) Awards. Rx Canada and their client (AstraZeneca Canada), the first international award winners, received awards for the Best Branded Compliance Program. The Health Inform(R) Programs for Crestor, Symbicort and Nexium medications were lauded for measurement of each program's effectiveness. "I really liked the way in which they measured and published their results," said Robert Nauman, BioPharma Advisors and a judge for the SPA awards. Rx Canada and their client (Eli Lilly Canada) received an innovation award for the Evista Inner Strength Program which ensured that pharmacists followed up with patients 2 weeks after their first intervention. Finally, AstraZeneca received an innovation award for the SERV(TM) Program, which is a platform that allows AZ brands to leverage the sales force to provide messages, tools and programs to physicians toward enhancing medication adherence in their patients.

The prestigious Strategic Patient Adherence (SPA) Awards co-sponsored by CBI and PharmaVoice were presented at the 7th Annual Forum on Patient Compliance, Adherence and Persistency held April 24th in Philadelphia, PA. These awards provided a forum that pays tribute to outstanding programs in the areas of patient compliance/adherence and persistency.

Awards were given to pharmaceutical organizations that met pre-defined criteria in 5 categories: Innovation, Quality, Measurement, Satisfaction, Health Outcomes & ROI. Programs that have been deemed exceptional in their compliance initiatives usually score above 60 points on the judging scale. Each entry was reviewed by this year's judging panel made up of Grant Corbett, Founder of Behavior Change Solutions, Inc., Robert Nauman, Principal at BioPharma Advisors, John Heilman, Senior Commercial Analytics Manager, New Practice and Corporate Analytics, AstraZeneca, Glenn Gary,
'/>"/>

SOURCE CBI Research, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
2. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
3. Beckman Coulter Announces First Quarter 2008 Results
4. Onyx Pharmaceuticals Announces First Quarter 2008 Financial Results Teleconference and Webcast
5. BioMarin Announces First Quarter 2008 Financial Results
6. Align Technology Announces $50 Million Stock Repurchase Program
7. Anesiva Announces New Zingo Marketing and Distribution Agreement
8. Premier Research Group plc and Octagon Research Solutions, Inc. Announce Strategic Partnership
9. Genomic Health to Announce First Quarter 2008 Financial Results and Host Conference Call on Tuesday, May 6, 2008
10. Webcast Alert: QIAGEN N.V. Announces First Quarter 2008 Earnings Conference Call
11. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Canna can: Ornamental eliminates pollutants from stormwater runoff 2Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Potential new heart attack biomarker uncovered 2Climate change could drive vast human migrations 8782 1Climate change could drive vast human migrations 8782 2Climate change could drive vast human migrations 8782 3 26amp 3B 238216 3BHairConfirm 26apos 3B Is First Drug Test of Its Kind to Report Low Medium High Usage 3B Now Available at Local Discount Drug Marts 48406 1 26amp 3B 238216 3BHairConfirm 26apos 3B Is First Drug Test of Its Kind to Report Low Medium High Usage 3B Now Available at Local Discount Drug Marts 48406 2 26amp 3B 238216 3BHairConfirm 26apos 3B Is First Drug Test of Its Kind to Report Low Medium High Usage 3B Now Available at Local Discount Drug Marts 48406 3New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 1New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 2New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 3New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 4New Study Shows Coaching to Patient Activation Levels Improves Disease Management Outcomes 48402 5